Dyne Therapeutics (NASDAQ:DYN) Trading Down 3%

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report)'s stock price was down 3% during mid-day trading on Thursday . The company traded as low as $27.57 and last traded at $27.89. Approximately 552,733 shares were traded during mid-day trading, a decline of 75% from the average daily volume of 2,206,098 shares. The stock had previously closed at $28.76.

Analyst Ratings Changes

A number of research analysts have issued reports on DYN shares. Stifel Nicolaus upped their target price on shares of Dyne Therapeutics from $35.00 to $41.00 and gave the company a "buy" rating in a report on Wednesday, March 6th. HC Wainwright reiterated a "buy" rating and set a $36.00 price objective on shares of Dyne Therapeutics in a report on Wednesday, March 6th. Chardan Capital increased their price objective on shares of Dyne Therapeutics from $20.00 to $31.00 and gave the stock a "buy" rating in a report on Friday, March 8th. Raymond James increased their price objective on shares of Dyne Therapeutics from $27.00 to $56.00 and gave the stock a "strong-buy" rating in a report on Thursday, January 4th. Finally, StockNews.com upgraded shares of Dyne Therapeutics to a "sell" rating in a report on Thursday, December 21st. One research analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $37.43.

Dyne Therapeutics Price Performance

The company's 50-day simple moving average is $24.95 and its 200-day simple moving average is $15.91. The company has a market cap of $2.17 billion, a price-to-earnings ratio of -6.74 and a beta of 0.95.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings data on Tuesday, March 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.17). Equities analysts predict that Dyne Therapeutics, Inc. will post -3.23 EPS for the current fiscal year.

Insider Transactions at Dyne Therapeutics

In related news, insider Wildon Farwell sold 5,493 shares of the firm's stock in a transaction on Monday, February 12th. The stock was sold at an average price of $25.07, for a total transaction of $137,709.51. Following the transaction, the insider now directly owns 163,503 shares in the company, valued at $4,099,020.21. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Dyne Therapeutics news, insider Wildon Farwell sold 5,493 shares of the firm's stock in a transaction on Monday, February 12th. The stock was sold at an average price of $25.07, for a total value of $137,709.51. Following the sale, the insider now directly owns 163,503 shares in the company, valued at $4,099,020.21. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Dirk Kersten bought 1,714,285 shares of the business's stock in a transaction on Tuesday, January 9th. The stock was bought at an average price of $17.50 per share, for a total transaction of $29,999,987.50. Following the completion of the purchase, the director now directly owns 6,416,793 shares of the company's stock, valued at approximately $112,293,877.50. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 1,888,532 shares of company stock valued at $44,687,450. 32.89% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Dyne Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Ameritas Investment Partners Inc. increased its holdings in shares of Dyne Therapeutics by 49.0% during the second quarter. Ameritas Investment Partners Inc. now owns 3,510 shares of the company's stock valued at $39,000 after purchasing an additional 1,155 shares during the period. Royal Bank of Canada increased its holdings in shares of Dyne Therapeutics by 72.8% during the second quarter. Royal Bank of Canada now owns 5,078 shares of the company's stock valued at $57,000 after purchasing an additional 2,140 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Dyne Therapeutics by 58.5% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,379 shares of the company's stock valued at $75,000 after purchasing an additional 3,092 shares during the period. Allspring Global Investments Holdings LLC increased its holdings in shares of Dyne Therapeutics by 95.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 9,310 shares of the company's stock valued at $83,000 after purchasing an additional 4,552 shares during the period. Finally, Sphera Funds Management LTD. acquired a new position in Dyne Therapeutics during the fourth quarter worth about $83,000. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.